Rhythm Pharmaceuticals' Shares Dive Following FDA's Verdict On IMCIVREE Drug

The U.S. Food and Drug Administration (FDA) has approved Rhythm Pharmaceuticals’ RYTM supplemental New Drug Application (sNDA) for IMCIVREE® (setmelanotide), a melanocortin-4 receptor (MC4R) agonist, for patients with Bardet-Biedl syndrome (BBS).

The regulatory approval was supported by data readout from pivotal Phase 3 clinical trial, which was the largest and longest interventional clinical trial in BBS, the trial met its primary endpoint and all key secondary endpoints.

David Meeker, M.D., Chair, President and Chief Executive Officer, stated, "This FDA approval represents a significant milestone for Rhythm, validating our strategy of developing IMCIVREE for people with hyperphagia and severe obesity caused by rare MC4R-pathway diseases and allowing us to provide our precision therapy to an established community of patients living with BBS and their families who are eagerly awaiting a new treatment option.”

Bardet-Biedl syndrome (BBS) is a rare genetic disease, that generates insatiable hunger, also known as hyperphagia, and severe obesity beginning early in life.

Rhythm also announced that the regulatory agency has issued a complete response letter (CRL) for the supplemental New Drug Application (sNDA) for setmelanotide in Alström syndrome. The company plans to reevaluate potential paths forward in Alström syndrome in the United States.

Commenting on the CRL issued by the FDA, Dr. Meeker, said, "We appreciate the FDA's careful review of our sNDA for IMCIVREE for the treatment of Alström syndrome, but are disappointed in this outcome, We are tremendously grateful to the Alström syndrome patients, caregivers and physicians who participated in our clinical development efforts and look forward to providing an update regarding our path forward.”

Rhythm Pharmaceuticals shares are trading down 10 percent at $3.51 in the after hours session.

Posted In: FDA ApprovalBiotechNewsPenny StocksHealth CareFDAGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.